Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 12
Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and address concerns they anticipate with the potential approval of BTKis for MS patients and strategies for mitigating these concerns.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
Now Viewing
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- There is only one FDA-approved option for primary progressive multiple sclerosis. What emerging therapies are under investigation for this subtype of MS?
- Discuss the PERSEUS trial, which is evaluating tolebrutinib in primary progressive multiple sclerosis.
- What are the potential adverse effects of BTKis and how should they be monitored for and managed?
- What access concerns do you anticipate with the potential approval of BTKis for patients with MS, and how can they be mitigated?
- Discuss considerations of BTKis in oncology and how these may relate to MS.
Related Videos
Related Content
